American International Group Inc. increased its holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Free Report) by 0.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,236,564 shares of the company’s stock after buying an additional 972 shares during the quarter. American International Group Inc. owned about 2.89% of Cullinan Therapeutics worth $12,601,000 at the end of the most recent reporting period.
A number of other institutional investors also recently bought and sold shares of CGEM. China Universal Asset Management Co. Ltd. increased its stake in shares of Cullinan Therapeutics by 352.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 4,954 shares of the company’s stock worth $50,000 after acquiring an additional 3,859 shares during the period. Vontobel Holding Ltd. acquired a new stake in Cullinan Therapeutics during the 4th quarter worth about $102,000. Annandale Capital LLC raised its stake in shares of Cullinan Therapeutics by 20.0% during the 3rd quarter. Annandale Capital LLC now owns 12,000 shares of the company’s stock valued at $109,000 after buying an additional 2,000 shares during the last quarter. Bailard Inc. acquired a new position in shares of Cullinan Therapeutics in the 4th quarter valued at about $110,000. Finally, Exchange Traded Concepts LLC lifted its holdings in shares of Cullinan Therapeutics by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 14,076 shares of the company’s stock valued at $143,000 after buying an additional 3,569 shares during the period. 86.31% of the stock is owned by hedge funds and other institutional investors.
Insider Buying and Selling
In other Cullinan Therapeutics news, insider Jennifer Michaelson sold 58,000 shares of the stock in a transaction that occurred on Monday, May 6th. The stock was sold at an average price of $28.07, for a total transaction of $1,628,060.00. Following the completion of the transaction, the insider now owns 129,582 shares of the company’s stock, valued at $3,637,366.74. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 6.07% of the stock is currently owned by insiders.
Wall Street Analysts Forecast Growth
View Our Latest Stock Report on Cullinan Therapeutics
Cullinan Therapeutics Stock Performance
Cullinan Therapeutics stock opened at $18.88 on Monday. The stock has a market capitalization of $1.09 billion, a P/E ratio of -6.03 and a beta of -0.06. The company’s fifty day moving average price is $22.49 and its 200 day moving average price is $16.87. Cullinan Therapeutics, Inc. has a 1 year low of $7.64 and a 1 year high of $30.19.
Cullinan Therapeutics (NASDAQ:CGEM – Get Free Report) last posted its quarterly earnings data on Wednesday, May 15th. The company reported ($0.86) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.90) by $0.04. Sell-side analysts predict that Cullinan Therapeutics, Inc. will post -3.02 EPS for the current year.
Cullinan Therapeutics Profile
Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.
See Also
- Five stocks we like better than Cullinan Therapeutics
- Top Biotech Stocks: Exploring Innovation Opportunities
- MarketBeat Week in Review – 6/10 – 6/14
- How is Compound Interest Calculated?
- Top 5 High-Performance Cryptocurrency ETFs to Watch
- How to Capture the Benefits of Dividend Increases
- 3 Stocks That Plummeted After the Post-Fed Speech Crash
Want to see what other hedge funds are holding CGEM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Free Report).
Receive News & Ratings for Cullinan Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cullinan Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.